Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Few People Changed Their Behaviour In The Early Stages Of The Swine Flu Outbreak
Few people changed their behaviour in the early stages of the swine flu outbreak, finds a study published on bmj.com. But the results do support efforts to inform the public about specific actions that can reduce the risks from swine flu and to communicate about the government"s plans and res.
generic viagra online
Shedding Light On Esophageal Disease
Canadian Light (CLS) staff scientist Luca Quaroni and Dr. Alan Casson, Head of the Department of Surgery at the University of Saskatchewan (U of S) used the synchrotron"s infrared microscope to identify tissue afflicted with a condition known as Barrett"s Esophagus from chemical fingerprints associated with the disease, which can lead to esophageal cancer. The finding is published in the June, 2009 issue of the Royal Society of Chemistry journal, The Analyst.
News of the day
Jellyfish Shed Fluorescent Light On How The Brain Works
Scientists at the University of Leicester are developing new ways of studying how brain cells work -thanks to jellyfish!
Health Insurance

NICE Upholds GlaxoSmithKline Appeal For Advanced Breast Cancer Treatment, Tyverb(R)(lapatinib)

The National Institute for Health and Clinical Excellence (NICE) announced that, following GlaxoSmithKline"s (GSK) appeal, it will reconsider the submission for Tyverb (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 GSK is pleased that NICE"s appeal panel agreed that the draft negative guidance should be reviewed, providing fresh hope for up to 2,000 women in the UK who could benefit from this effective treatment on the NHS. Dr Alison Jones, Medical Oncologist at the University College London Hospital and the Royal Free Hospital commented: "It is great that NICE will reconsider the evidence supporting the use of lapatinib as there is a significant unmet medical need for women with this aggressive form of advanced breast cancer. These women have very few treatment options left available to them and lapatinib, when combined with capecitabine, offers a chance of additional time without their disease progressing." The appeal has been upheld in light of new supplementary NICE advice for the assessment of treatments in small patient populations with a short life expectancy, issued in January this year.2 The appeal panel agreed that GSK and other consultees should be given the opportunity to make a full submission under these new "end of life" criteria.1 Simon Jose, General Manager, GSK UK commented: "We welcome the decision of the appeal panel and the opportunity to make a full submission to NICE under the end of life criteria. We appreciate that NICE has some very tough decisions to make, especially in this end of life setting, but given the considerable survival benefits that Tyverb offers these women, we believe it deserves full and thorough consideration." In line with previous commitments, GSK UK will continue to offer the Tyverb Patient Access Programme to both NICE and individual NHS Trusts. Under this scheme GSK bears the cost of lapatinib for up to the first 12 weeks of treatment, Safety Information Lapatinib plus capecitabine is generally well tolerated. The most common adverse events associated with lapatinib plus capecitabine were diarrhoea, rash, nausea, vomiting, fatigue and hand-foot syndrome.3,4 Diarrhoea and rash were more common with the combination whilst the incidence of hand-foot syndrome was similar between the two treatment groups.3 A decrease in left ventricular ejection fraction (LVEF) was reported by 2.5% of patients receiving lapatinib plus capecitabine vs. 1% of patients on capecitabine alone.3 Hepatobiliary events (mainly raised liver enzymes and/or bilirubin levels) have been reported commonly in association with lapatinib plus capecitabine therapy.3 Lapatinib has also been associated with reports of pulmonary toxicity. About Tyverb ò€¢ Tyverb received a conditional marketing authorisation in Europe, June 2008.3 ò€¢ Tyverb, in combination with capecitabine, is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress ErbB2 (HER2). Patients should have progressive disease following prior therapy which must include anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.3 ò€¢ Healthcare professionals should refer to the Tyverb Summary of Characteristics (SPC) for full prescribing information, including warnings and precautions.3 GlaxoSmithKline - one of the world"s leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com Tyverb® is a registered trademark of the GlaxoSmithKline group of companies. References 1. Lapatinib for the treatment of women with previously treated advanced or metastatic breast cancer. NICE Appeal Panel"s decision, 9 July 2009 http://guidance.nice.org.uk/TA/Wave13/1 2. Appraising life extending end of life treatments. January 2009. http://www.nice.org.uk/media/88A/F2/SupplementaryAdviceTACEoL.pdfAccessed 8 July 2009 3. Tyverb® (lapatinib) Summary of Product Characteristics. http://emc.medicines.org.uk/medicine/20929/SPC/Tyverb Last accessed 05 June 2009 4. Cameron D, Casey M, Press M, et al. A phase III randomised comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112:533-543 GlaxoSmithKline


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009